Compare OXSQ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | IPHA |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.9M | 141.7M |
| IPO Year | N/A | N/A |
| Metric | OXSQ | IPHA |
|---|---|---|
| Price | $1.90 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 1.1M | 23.6K |
| Earning Date | 04-29-2026 | 03-26-2026 |
| Dividend Yield | ★ 22.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.61 | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.56 | $1.18 |
| 52 Week High | $2.59 | $2.63 |
| Indicator | OXSQ | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 62.02 | 46.46 |
| Support Level | $1.67 | $1.18 |
| Resistance Level | $1.95 | $1.80 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 66.73 | 23.26 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.